$0.48
+0.01
(+2.13%)▲
Live
3.73%
Downside
Day's Volatility :5.48%
Upside
1.82%
11.46%
Downside
52 Weeks Volatility :77.98%
Upside
75.13%
Period | Bioline Rx Ltd | Index (Russel 2000) |
---|---|---|
3 Months | -42.17% | 0.0% |
6 Months | -30.6% | 0.0% |
1 Year | -64.67% | 0.0% |
3 Years | -84.54% | -23.0% |
Market Capitalization | 39.8M |
Book Value | $0.01 |
Earnings Per Share (EPS) | -0.45 |
PEG Ratio | 0.2 |
Wall Street Target Price | 9.83 |
Profit Margin | -176.67% |
Operating Margin TTM | -107.05% |
Return On Assets TTM | -35.23% |
Return On Equity TTM | -171.94% |
Revenue TTM | 17.0M |
Revenue Per Share TTM | 0.24 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -33.1M |
Diluted Eps TTM | -0.45 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.35 |
EPS Estimate Next Year | -0.38 |
EPS Estimate Current Quarter | -0.14 |
EPS Estimate Next Quarter | -0.1 |
What analysts predicted
Upside of 1947.92%
Sell
Neutral
Buy
Bioline Rx Ltd is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Bioline Rx Ltd | -26.9% | -30.6% | -64.67% | -84.54% | -82.85% |
Regeneron Pharmaceuticals, Inc. | -9.28% | 10.06% | 24.53% | 74.0% | 232.45% |
Novo Nordisk A/s | -4.54% | -5.72% | 21.59% | 126.2% | 349.01% |
Alnylam Pharmaceuticals, Inc. | 8.87% | 102.98% | 82.67% | 44.83% | 241.09% |
Vertex Pharmaceuticals Incorporated | 5.0% | 20.77% | 31.37% | 158.16% | 163.17% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Bioline Rx Ltd | NA | NA | 0.2 | -0.35 | -1.72 | -0.35 | NA | 0.01 |
Regeneron Pharmaceuticals, Inc. | 26.41 | 26.41 | 1.37 | 44.9 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 40.21 | 40.21 | 1.81 | 3.36 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.42 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.59 | 0.18 | -0.03 | 0.13 | NA | 57.26 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Bioline Rx Ltd | NA | $39.8M | -82.85% | NA | -176.67% |
Regeneron Pharmaceuticals, Inc. | Buy | $110.0B | 232.45% | 26.41 | 32.04% |
Novo Nordisk A/s | Buy | $529.8B | 349.01% | 40.21 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $38.1B | 241.09% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $128.7B | 163.17% | 32.84 | -4.74% |
Insights on Bioline Rx Ltd
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 82.9% return, outperforming this stock by 148.3%
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 44.8% return, outperforming this stock by 129.3%
Alyeska Investment Group, L.P.
CVI Holdings LLC
Envestnet Asset Management Inc
Values First Advisors Inc
Susquehanna International Group, LLP
Atria Investments LLC
biolinerx is a clinical-stage, publicly-traded (nasdaq/ tase: blrx) biopharmaceutical development company based in modi'in, israel. this website or social media page (the “site”) of biolinerx ltd. (the “company”) may contain content posted by a third party or links to third party websites (the “content” or “third party content”). this content is provided solely for general informational purposes as a convenience to you and not as an endorsement by the company of the content. it does not constitute a recommendation or solicitation to purchase or sell any security or make any other type of investment or investment decision. the company is not responsible for this content and does not make any representations as to the subject matter, accuracy, completeness or timeliness or the content. if you decide to access linked third party websites, you do so at your own risk. there is no warranty of any kind, express or implied, regarding the content, including without limitation any warranty of m
Organization | Bioline Rx Ltd |
Employees | 79 |
CEO | Mr. Philip A. Serlin CPA, M.B.A., CPA, MBA |
Industry | Health Technology |
Jpmorgan Betabuilders 1-5 Year Us Aggregate Bd Etf
$0.48
+2.13%
Invesco Bulletshares 2025 Hi
$0.48
+2.13%
Schwab International Dividend Equity Etf
$0.48
+2.13%
Blockchain Coinvestors Acquisition Corp.
$0.48
+2.13%
Allgiant Travel Company
$0.48
+2.13%
Rogers Corp
$0.48
+2.13%
Innovator Intl Developed 10 Buffer Etf - Quarterly
$0.48
+2.13%
Iheartmedia
$0.48
+2.13%
Lightpath Technologies Inc
$0.48
+2.13%